Full-Time

Associate Director

Drug Product

Posted on 11/13/2024

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech company developing innovative medicines

AI & Machine Learning
Biotechnology

Compensation Overview

$170k - $186.2kAnnually

+ Bonus + Equity Compensation

Senior, Expert

San Bruno, CA, USA + 1 more

More locations: Hayward, CA, USA

Positions will be moving from Hayward, CA to Millbrae, CA starting April 2025.

Category
Public Health
Biology Lab & Research
Biology & Biotech

You match the following Eikon Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Post graduate degree (PhD preferred) in Pharmaceutics, Chemical Engineering, or related field
  • 7+ years of experience in pharmaceutical formulation and drug product development
  • Experience with various dosage forms (solid oral, injectable, etc.)
  • Proven track record of successful FIH formulation development and regulatory submissions
  • Strong understanding of FDA and EMA regulatory requirements and quality systems
  • Excellent communication, leadership, and problem-solving skills
  • Hands-on knowledge of analytical methods and quality control processes
  • Ability to work in a fast-paced, dynamic environment and manage multiple priorities
  • Excellent interpersonal and communication skills, capable of leading and motivating teams
Responsibilities
  • Lead the in-house preclinical formulation development, and drug product development from early clinical stage through commercial stages
  • Oversee formulation development and scale-up activities at CDMOs
  • Ensure robust and scalable manufacturing processes are in place
  • Collaborate with cross-functional teams including Research Project Teams, Regulatory Affairs, Quality Assurance, Manufacturing, Supply Chain and Clinical Operations to ensure seamless product development and scale-up
  • Develop and execute project plans, timelines, and budgets
  • Ensure all CMC activities comply with regulatory requirements (FDA, EMA, etc.)
  • Prepare and review CMC sections of regulatory submissions, including INDs, NDAs, and BLAs
  • Interact with regulatory agencies to address CMC-related queries and provide necessary documentation
  • Provide technical expertise drug product formulation and manufacturing
  • Mentor and develop junior staff members
  • Identify and manage external partners, including CMOs and CROs
  • Ensure quality and timely delivery of contracted services
  • Negotiate contracts and manage vendor performance
Desired Qualifications
  • Pre-clinical formulation knowledge is strongly preferred

Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. The company's goal is to leverage advanced technologies to address unmet medical needs.

Company Size

201-500

Company Stage

Series C

Total Funding

$750.8M

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon's partnership with Impact Therapeutics expands their therapeutic pipeline.
  • Michael Klobuchar's appointment as COO may enhance strategic operations.
  • Expansion into Jersey City office space supports increased R&D activities.

What critics are saying

  • Competition from biotech unicorns like Abogen Biosciences is intensifying.
  • Integrating new clinical-stage assets may delay drug development timelines.
  • Expansion into new office space could increase operational costs.

What makes Eikon Therapeutics unique

  • Eikon's SMT platform offers real-time visualization of protein motion in living cells.
  • The company integrates biology, engineering, and chemistry for novel drug discovery.
  • Eikon's diverse team combines expertise across multiple scientific and engineering disciplines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

3%
Business Wire
Jan 7th, 2025
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Business Wire
Nov 20th, 2024
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer

Eikon Therapeutics announces appointment of Michael klobuchar as Chief Operating Officer.

Labiotech
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing

ROI-NJ
Jan 17th, 2024
Hyundai, Eikon Therapeutics, Bank Of Montreal And Arco Design All Sign Leases At Class A Office Tower In Jersey City

Cushman & Wakefield said Tuesday that it arranged three new long-term leases and one lease renewal totaling 62,131 square feet at 3 Second St., a 600,000-square-foot Class A office tower in Jersey City.Hyundai Motor America signed a 12,580-square-foot lease on the fifth floor.In addition, Eikon Therapeutics signed a 36,284-square-foot lease on the fourth floor. Bank of Montreal renewed its 10,365-square-foot lease on the 12th floor. And Arco Design/Build signed a 2,902-square-foot lease on the eighth floor.Cushman & Wakefield’s David DeMatteis, Robert Rudin, Mina Shehata and Dirk Hrobsky represented the landlord, funds managed by Ares Management, in the transactions. William O’Keefe, Raymond Trevisan and Don Yahn, also of Cushman & Wakefield, represented Hyundai.“We are thrilled to welcome new tenants and to expand relationships with existing ones to enhance 3 Second St.’s impressive tenant roster,” DeMatteis said. “These leases are further evidence that the best located, highly amenitized buildings attract tenants. The Ares Management Real Estate Group has provided a hands-on approach to ownership and is constantly reinvesting in this asset with hospitality-focused upgrades, including a new, thoughtfully designed tenant sky lounge that is currently underway.”3 Second St

PharmiWeb
Dec 18th, 2023
Eikon Therapeutics To Present At The 42Nd Annual J.P. Morgan Healthcare Conference

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE. PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site

PharmiWeb
Dec 1st, 2023
Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors

Eikon Therapeutics announces the election of Robert L. Huffines to its Board of directors.

Business Wire
Jun 2nd, 2023
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline

Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and sc

Lilly Asia Ventures
Jun 2nd, 2023
Impact Therapeutics entered into global partnership with Eikon Therapeutics to develop and commercialize PARP1 selective inhibitors

Impact Therapeutics entered into global partnership with Eikon Therapeutics to develop and commercialize PARP1 selective inhibitors.

Pharmafocus Europe
Jun 2nd, 2023
PARP1 Selective Inhibitors | Pharma Europe News

IMPACT Therapeutics and Eikon Therapeutics have recently announced a global license and collaboration agreement for the development of PARP1 selective inhibitors, including IMP1734.

BioSpace
Jun 1st, 2023
Eikon Therapeutics Builds Leading Clinical Development Organization With Appointment Of Senior Team With Extensive Industry Expertise | Biospace

Under the leadership of Roy Baynes, experienced team of industry veterans is poised to successfully move assets through clinical development and regulatory reviewHAYWARD, Calif.--(BUSINESS WIRE)-- Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review. Eikon recently announced its development pipeline, which includes a number of acquired clinical and preclinical stage assets that complement its discovery-stage programs.“In support of our vision to build a global biotechnology company focused on developing important new medicines, we have recruited a sophisticated team of industry experts who have decades of collective experience in managing every component of advancing new drug candidates from their earliest stages through the clinic to regulatory approval,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “This team is fully integrated within our organization and is working alongside our advanced engineering and research team, who have dramatically accelerated the performance of our pioneering Single Molecule Tracking (SMT) technology. Together, they position Eikon to become a fully integrated global biotechnology company.”Baynes added, “I am incredibly proud of the team we are building here at Eikon

INACTIVE